DDInter438 DDInter1491
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Conivaptan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Conivaptan {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Pomalidomide
Conivaptan {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Conivaptan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Conivaptan {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Conivaptan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Conivaptan {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Cabozantinib {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Conivaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Conivaptan {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Nilotinib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Conivaptan {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Nilotinib {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Pomalidomide
Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pomalidomide (Compound)
Conivaptan (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Pomalidomide (Compound)
Conivaptan (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Conivaptan may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pomalidomide (Compound)
Conivaptan may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound)
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Conivaptan may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pomalidomide (Compound)
Conivaptan may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Pomalidomide (Compound)